Weekly Cardiology Research Analysis
This week’s cardiology literature highlights rapid progress across mechanistic biology, pragmatic therapeutics, and precision diagnostics. High-impact translational work identified endothelial PCSK5 as a druggable VEGFA-activating axis for post-infarction angiogenesis, while a pragmatic randomized POLY-HF trial showed a fixed-dose heart-failure polypill improved EF, adherence, and reduced events in underserved patients. Complementary human and large-animal studies nominated NOD1 as a cardiomyocy
Summary
This week’s cardiology literature highlights rapid progress across mechanistic biology, pragmatic therapeutics, and precision diagnostics. High-impact translational work identified endothelial PCSK5 as a druggable VEGFA-activating axis for post-infarction angiogenesis, while a pragmatic randomized POLY-HF trial showed a fixed-dose heart-failure polypill improved EF, adherence, and reduced events in underserved patients. Complementary human and large-animal studies nominated NOD1 as a cardiomyocyte-centered innate-immune driver of atrial myopathy, opening a new target for AF/atrial remodeling.
Selected Articles
1. PCSK5 promotes angiogenesis and cardiac repair after myocardial infarction.
This mechanistic translational study identifies endothelial PCSK5 as a secreted, pro-angiogenic factor that directly cleaves and activates VEGFA, promoting angiogenesis and functional recovery after myocardial infarction. Endothelial Pcsk5 loss impaired repair in animal models, while endothelial-specific delivery and semaglutide treatment enhanced vascular density and function.
Impact: First clear demonstration that PCSK5 directly activates VEGFA signaling to drive post-infarction repair, revealing a druggable endothelial–paracrine axis with translational potential.
Clinical Implications: PCSK5 could become a biomarker and therapeutic target to enhance post-MI angiogenesis; GLP-1R agonists' partial effect via endothelial Pcsk5 suggests repurposing or combination strategies to accelerate repair pending human validation.
Key Findings
- Plasma PCSK5 is elevated in MI patients and associates with cardiac function improvement.
- Endothelial Pcsk5 deficiency impairs angiogenesis and recovery post-MI; endothelial-specific Pcsk5 delivery enhances repair.
- PCSK5 directly cleaves VEGFA; Arg158 and Asn164 residues are essential for activity.
- Semaglutide increased vascular density and function partly via endothelial Pcsk5 in mice.
2. Polypill for heart failure with reduced ejection fraction: the POLY-HF randomized trial.
A pragmatic, open-label randomized trial in predominantly underserved HFrEF patients showed a once-daily polypill (metoprolol succinate, spironolactone 12.5 mg, empagliflozin 10 mg) improved cardiac MRI–derived LVEF at 6 months (between-group difference 3.3 percentage points), halved HF hospital/ED visits, and markedly increased drug-level–verified adherence versus rapid uptitration of individual agents.
Impact: Pragmatic RCT evidence that therapeutic simplification via a fixed-dose polypill can close implementation gaps—improving adherence and intermediate clinical outcomes in HFrEF—addressing a major public-health barrier.
Clinical Implications: A heart-failure polypill may enable rapid, equitable delivery of core HFrEF therapies, improve adherence, and reduce hospital visits—supporting scale-up studies, cost-effectiveness evaluation, and inclusion in guideline implementation research.
Key Findings
- Polypill improved LVEF vs enhanced usual care (between-group difference 3.3 percentage points; p=0.039).
- Heart failure hospitalizations or ED visits were 60% lower with the polypill (adjusted rate ratio 0.40).
- Adherence by drug-level verification was higher with polypill (79% vs 54%) with fewer adverse events.
3. NOD1 is a key mediator of atrial myopathy in heart failure.
Multispecies mechanistic work (human atrial tissue, porcine models, mouse genetics, pharmacologic inhibition) implicates NOD1 activation in atrial structural remodeling, Ca2+ mishandling and profibrotic signaling via a CaMKII–RyR2 (Ser2814) pathway. Genetic deletion or pharmacologic inhibition of NOD1 prevented atrial dysfunction and remodeling in preclinical models.
Impact: Identifies a cardiomyocyte-centered innate immune mechanism (NOD1–CaMKII–RyR2) with convergent human and large-animal validation and both genetic and pharmacologic modulation, pointing to a novel therapeutic axis for atrial myopathy and AF progression.
Clinical Implications: NOD1 inhibition could be developed as a mechanism-based therapy to prevent or attenuate atrial remodeling and AF progression in heart failure, pending development of selective inhibitors and clinical trials with atrial endpoints.
Key Findings
- NOD1 is markedly upregulated in human HF atrial myocardium and two porcine atrial myopathy models.
- Cardiomyocyte NOD1 deficiency or pharmacologic inhibition prevents atrial dysfunction, profibrotic signaling, and Ca2+ mishandling after injury.
- NOD1 activation induces CaMKII-dependent RyR2-Ser2814 hyperphosphorylation; CaMKII inhibition abrogates these effects.